Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication - results from the CAVASIC Study

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 428-435

  Rantner, Barbara ^a   Pohlhammer, Johannes ^a   Stadler, Marietta ^b,e   Peric, Slobodan ^b   Hammerer Lercher, Angelika ^c   Klein Weigel, Peter ^d   Fraedrich, Gustav ^a   Kronenberg, Florian ^a   Kollerits, Barbara ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hietzing Hospital   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Cardiovascular disease; Left ventricular ejection fraction; Mortality; Peripheral arterial disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN T; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SMOKING; SURVIVAL RATE; AGED; AUSTRIA; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME;

AGED; AUSTRIA; BIOMARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERMITTENT CLAUDICATION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PERIPHERAL ARTERIAL DISEASE; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84922647878     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.060     Document Type: Article

References (42)

1. Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003, 108(8):977-982.
2. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289(2):194-202.
3. Yeboah J., Rodriguez C.J., Stacey B., Lima J.A., Liu S., Carr J.J., et al. Prognosis of individuals with asymptomatic left ventricular systolic dysfunction in the multi-ethnic study of atherosclerosis (MESA). Circulation 2012, 126(23):2713-2719.
4. Ahn S.A., Jong P., Yusuf S., Bangdiwala S.I., Pouleur H.G., Rousseau M.F. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. J.Am. Coll. Cardiol. 2006, 47(9):1904-1905.
5. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem D., Kostis J., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340(8829):1173-1178.
6. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N.Engl. J. Med. 1992, 327(10):669-677.
7. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur. Heart J. 2012, 33(14):1787-1847.
8. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N.Engl. J. Med. 2002, 347(18):1397-1402.
9. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation 2009, 119(14):1977-2016.
10. Hertzer N.R., Beven E.G., Young J.R., O'Hara P.J., Ruschhaupt W.F., Graor R.A., et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann. Surg. 1984, 199(2):223-233.
11. Jain K.M., Patil K.D., Doctor U.S., Peck S.L. Preoperative cardiac screening before peripheral vascular operations. Am. Surg. 1985, 51(2):77-79.
12. Ward R.P., Goonewardena S.N., Lammertin G., Lang R.M. Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. Am. J. Cardiol. 2007, 99(4):499-503.
13. Ward R.P., Min J.K., McDonough K.M., Lang R.M. High prevalence of important cardiac findings in patients with peripheral arterial disease referred for echocardiography. J.Am. Soc. Echocardiogr. 2005, 18(8):844-849.
14. Baron J.F., Mundler O., Bertrand M., Vicaut E., Barre E., Godet G., et al. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. N.Engl. J. Med. 1994, 330(10):663-669.
15. Hedberg P., Hammar C., Selmeryd J., Viklund J., Leppert J., Hellberg A., Henriksen E. Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease. Eur. J. Heart Fail 2014, 16(6):625-632.
16. Feringa H.H., Elhendy A., Karagiannis S.E., Noordzij P.G., Dunkelgrun M., Schouten O., et al. Improving risk assessment with cardiac testing in peripheral arterial disease. Am. J. Med. 2007, 120(6):531-538.
17. Rantner B., Kollerits B., nderwald-Stadler M., Klein-Weigel P., Gruber I., Gehringer A., et al. Association between the UGT1A1 TA-repeat polymorphism and Bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin. Chem. 2008, 54(5):851-857.
18. Kollerits B., Sturm G., Lamina C., Hammerer-Lercher A., Rantner B., Stadler M., et al. Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study. Clin. Chem. 2013, 59(4):692-702.
19. Amico A.F., Lichtenberg G.S., Reisner S.A., Stone C.K., Schwartz R.G., Meltzer R.S. Superiority of visual versus computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. Am. Heart J. 1989, 118(6):1259-1265.
20. Jensen-Urstad K., Bouvier F., Hojer J., Ruiz H., Hulting J., Samad B., et al. Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. Am. J. Cardiol. 1998, 81(5):538-544.
21. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J.Am. Soc. Echocardiogr. 2005, 18(12):1440-1463.
22. Brevetti G., Schiano V., Verdoliva S., Silvestro A., Sirico G., De M.J., et al. Peripheral arterial disease and cardiovascular risk in Italy. Results of the peripheral arteriopathy and cardiovascular events (PACE) study. J.Cardiovasc Med. Hagerst.) 2006, 7(8):608-613.
23. Dormandy J., Mahir M., Ascady G., Balsano F., De L.P., Blombery P., et al. Fate of the patient with chronic leg ischaemia. A review article. J.Cardiovasc Surg. (Torino) 1989, 30(1):50-57.
24. Dormandy J.A., Rutherford R.B. Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic inter-society consensus (TASC). J.Vasc. Surg. 2000, 31(1 Pt 2):S1-S296.
25. Ingolfsson I.O., Sigurdsson G., Sigvaldason H., Thorgeirsson G., Sigfusson N. Amarked decline in the prevalence and incidence of intermittent claudication in icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol-the Reykjavik study. J.Clin. Epidemiol. 1994, 47(11):1237-1243.
26. Smith G.D., Shipley M.J., Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall study. Circulation 1990, 82(6):1925-1931.
27. Lamina C., Meisinger C., Heid I.M., Lowel H., Rantner B., Koenig W., Kronenberg F. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur. Heart J. 2006, 27(21):2580-2587.
28. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. experimental observations and clinical implications. Circulation 1990, 81(4):1161-1172.
29. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100(9):999-1008.
30. Ng L.L., Loke I.W., Davies J.E., Geeranavar S., Khunti K., Stone M.A., et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J.Am. Coll. Cardiol. 2005, 45(7):1043-1050.
31. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002, 288(10):1252-1259.
32. de Lemos J.A., McGuire D.K., Khera A., Das S.R., Murphy S.A., Omland T., Drazner M.H. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas heart study. Am. Heart J. 2009, 157(4):746-753.
33. Goetze J.P., Mogelvang R., Maage L., Scharling H., Schnohr P., Sogaard P., et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur. Heart J. 2006, 27(24):3004-3010.
34. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J.Am. Coll. Cardiol. 2004, 43(6):1019-1026.
35. de Lemos J.A., Drazner M.H., Omland T., Ayers C.R., Khera A., Rohatgi A., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010, 304(22):2503-2512.
36. Mueller T., Dieplinger B., Poelz W., Endler G., Wagner O.F., Haltmayer M. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the linz peripheral arterial disease Study. Clin. Chem. 2009, 55(1):68-77.
37. Linnemann B., Sutter T., Herrmann E., Sixt S., Rastan A., Schwarzwaelder U., et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. J.Am. Coll. Cardiol. 2014, 63(15):1529-1538.
38. Creager M.A., Belkin M., Bluth E.I., Casey D.E., Chaturvedi S., Dake M.D., et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American college of cardiology foundation/American heart association task force on clinical data standards (Writing committee to develop clinical data standards for peripheral atherosclerotic vascular disease). Circulation 2012, 125(2):395-467.
39. Thatipelli M.R., Pellikka P.A., McBane R.D., Rooke T.W., Rosales G.A., Hodge D., et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J.Vasc. Surg. 2007, 46(1):62-70.
40. van Kuijk J.P., Flu W.J., Valentijn T.M., Chonchol M., Kuiper R.J., Verhagen H.J., et al. Influence of left ventricular dysfunction (diastolic versus systolic) on long-term prognosis in patients with versus without diabetes mellitus having elective peripheral arterial surgery. Am. J. Cardiol. 2010, 106(6):860-864.
41. Darbar D., Gillespie N., Main G., Bridges A.B., Kennedy N.S., Pringle T.H., McNeill G.P. Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. Am. J. Cardiol. 1996, 78(7):736-740.
42. Rose E.L., Liu X.J., Henley M., Lewis J.D., Raftery E.B., Lahiri A. Prognostic value of noninvasive cardiac tests in the assessment of patients with peripheral vascular disease. Am. J. Cardiol. 1993, 71(1):40-44.